Do analysts rate IMCC or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, IMCC or VCNX?

IM Cannabis has higher revenue and earnings than Vaccinex. IM Cannabis is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.02 -$8.10M -$2.02 N/A Vaccinex $388K 6.70 -$20.25M -$48.27 N/A

Is IMCC or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Vaccinex's return on equity of 0.00% beat IM Cannabis' return on equity. Company Net Margins Return on Equity Return on Assets IM Cannabis -39.62% -585.96% -58.32% Vaccinex N/A N/A -383.58%

Do analysts rate IMCC or CASI?

CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend IMCC or CANF?

Can-Fite BioPharma has a consensus target price of $44.00, indicating a potential upside of 1,283.65%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend IMCC or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, IMCC or CDT?

IM Cannabis has higher revenue and earnings than CDT Equity. IM Cannabis is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.02 -$8.10M -$2.02 N/A CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A

Is IMCC or CDT more profitable?

CDT Equity has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. CDT Equity's return on equity of -72.25% beat IM Cannabis' return on equity. Company Net Margins Return on Equity Return on Assets IM Cannabis -39.62% -585.96% -58.32% CDT Equity N/A -72.25% -55.44%

Does the media refer more to IMCC or CDT?

In the previous week, CDT Equity had 5 more articles in the media than IM Cannabis. MarketBeat recorded 8 mentions for CDT Equity and 3 mentions for IM Cannabis. CDT Equity's average media sentiment score of 0.89 beat IM Cannabis' score of 0.62 indicating that CDT Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IMCC or CMND?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to IMCC or CMND?

In the previous week, Clearmind Medicine had 1 more articles in the media than IM Cannabis. MarketBeat recorded 4 mentions for Clearmind Medicine and 3 mentions for IM Cannabis. Clearmind Medicine's average media sentiment score of 0.99 beat IM Cannabis' score of 0.62 indicating that Clearmind Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clearmind Medicine 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

IM Cannabis (IMCC) Competitors

$3.06 -0.35 (-10.26%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$3.13 +0.07 (+2.29%)

As of 07:10 AM Eastern

Compare

IMCC vs. VCNX, CASI, CANF, CDT, and CMND

Should you buy IM Cannabis stock or one of its competitors? IM Cannabis's main competitors and comparable companies include Vaccinex (VCNX), CASI Pharmaceuticals (CASI), Can-Fite BioPharma (CANF), CDT Equity (CDT), and Clearmind Medicine (CMND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does IM Cannabis compare to Vaccinex?

IM Cannabis (NASDAQ:IMCC) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

In the previous week, IM Cannabis had 3 more articles in the media than Vaccinex. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Vaccinex. IM Cannabis' average media sentiment score of 0.62 beat Vaccinex's score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
IM Cannabis	Positive
Vaccinex	Neutral

IM Cannabis has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Vaccinex. IM Cannabis is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$2.02	N/A
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vaccinex has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Vaccinex's return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
Vaccinex	N/A	N/A	-383.58%

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IM Cannabis beats Vaccinex on 8 of the 14 factors compared between the two stocks.

How does IM Cannabis compare to CASI Pharmaceuticals?

IM Cannabis (NASDAQ:IMCC) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IM Cannabis has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

IM Cannabis has a net margin of -39.62% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

In the previous week, IM Cannabis had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for CASI Pharmaceuticals. IM Cannabis' average media sentiment score of 0.62 beat CASI Pharmaceuticals' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
IM Cannabis	Positive
CASI Pharmaceuticals	Neutral

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IM Cannabis has higher revenue and earnings than CASI Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$2.02	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Summary

IM Cannabis beats CASI Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does IM Cannabis compare to Can-Fite BioPharma?

IM Cannabis (NASDAQ:IMCC) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Can-Fite BioPharma has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Can-Fite BioPharma's return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
Can-Fite BioPharma	N/A	N/A	N/A

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, IM Cannabis had 3 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Can-Fite BioPharma. IM Cannabis' average media sentiment score of 0.62 beat Can-Fite BioPharma's score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
IM Cannabis	Positive
Can-Fite BioPharma	Neutral

IM Cannabis has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Can-Fite BioPharma has a consensus target price of $44.00, indicating a potential upside of 1,283.65%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Can-Fite BioPharma has lower revenue, but higher earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$2.02	N/A
Can-Fite BioPharma	$405K	5.14	-$7.63M	-$22.80	N/A

Summary

Can-Fite BioPharma beats IM Cannabis on 10 of the 16 factors compared between the two stocks.

How does IM Cannabis compare to CDT Equity?

IM Cannabis (NASDAQ:IMCC) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IM Cannabis has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, CDT Equity had 5 more articles in the media than IM Cannabis. MarketBeat recorded 8 mentions for CDT Equity and 3 mentions for IM Cannabis. CDT Equity's average media sentiment score of 0.89 beat IM Cannabis' score of 0.62 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IM Cannabis has higher revenue and earnings than CDT Equity. IM Cannabis is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$2.02	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

CDT Equity has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. CDT Equity's return on equity of -72.25% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
CDT Equity	N/A	-72.25%	-55.44%

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 7.3% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CDT Equity beats IM Cannabis on 7 of the 12 factors compared between the two stocks.

How does IM Cannabis compare to Clearmind Medicine?

IM Cannabis (NASDAQ:IMCC) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

IM Cannabis has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Clearmind Medicine has lower revenue, but higher earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$2.02	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

In the previous week, Clearmind Medicine had 1 more articles in the media than IM Cannabis. MarketBeat recorded 4 mentions for Clearmind Medicine and 3 mentions for IM Cannabis. Clearmind Medicine's average media sentiment score of 0.99 beat IM Cannabis' score of 0.62 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clearmind Medicine	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Clearmind Medicine has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Clearmind Medicine's return on equity of -143.79% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
Clearmind Medicine	N/A	-143.79%	-88.51%

Summary

Clearmind Medicine beats IM Cannabis on 7 of the 12 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCC vs. The Competition

Export

Metric	IM Cannabis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$710K	$12.20B	$7.20B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	10.96%
P/E Ratio	-0.05	785.16	272.60	25.50
Price / Sales	0.02	758.14	626.13	97.73
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	-0.21	10.54	11.03	6.34
Net Income	-$8.10M	$2.83B	$3.47B	$349.45M
7 Day Performance	-7.27%	-0.93%	0.12%	-0.67%
1 Month Performance	-11.92%	5.14%	8.14%	4.48%
1 Year Performance	-95.60%	5.97%	24.11%	14.94%

IM Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCC IM Cannabis	0.4208 of 5 stars	$3.06 -10.3%	N/A	-95.6%	$710K	$39.17M	N/A	340
VCNX Vaccinex	N/A	$1.00 flat	N/A	+100.0%	$2.60M	$388K	N/A	40	High Trading Volume
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
CANF Can-Fite BioPharma	N/A	$3.40 -2.3%	$44.00 +1,194.1%	-74.8%	$2.23M	$405K	N/A	8
CDT CDT Equity	0.6722 of 5 stars	$2.93 -2.7%	N/A	-99.9%	$1.85M	N/A	N/A	3	Positive News Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IM Cannabis (IMCC) Competitors

IMCC vs. VCNX, CASI, CANF, CDT, and CMND

How does IM Cannabis compare to Vaccinex?

Summary

How does IM Cannabis compare to CASI Pharmaceuticals?

Summary

How does IM Cannabis compare to Can-Fite BioPharma?

Summary

How does IM Cannabis compare to CDT Equity?

Summary

How does IM Cannabis compare to Clearmind Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IM Cannabis (IMCC) Competitors

IMCC vs. VCNX, CASI, CANF, CDT, and CMND

How does IM Cannabis compare to Vaccinex?

Does the media refer more to IMCC or VCNX?

Which has more volatility & risk, IMCC or VCNX?

Which has higher earnings & valuation, IMCC or VCNX?

Do analysts rate IMCC or VCNX?

Is IMCC or VCNX more profitable?

Do insiders and institutionals hold more shares of IMCC or VCNX?

Summary

How does IM Cannabis compare to CASI Pharmaceuticals?

Do analysts rate IMCC or CASI?

Which has more risk and volatility, IMCC or CASI?

Is IMCC or CASI more profitable?

Does the media refer more to IMCC or CASI?

Do insiders & institutionals hold more shares of IMCC or CASI?

Which has preferable valuation & earnings, IMCC or CASI?

Summary

How does IM Cannabis compare to Can-Fite BioPharma?

Is IMCC or CANF more profitable?

Do insiders and institutionals have more ownership in IMCC or CANF?

Does the media prefer IMCC or CANF?

Which has more risk & volatility, IMCC or CANF?

Do analysts recommend IMCC or CANF?

Which has better valuation & earnings, IMCC or CANF?

Summary

How does IM Cannabis compare to CDT Equity?

Do analysts recommend IMCC or CDT?

Which has more volatility and risk, IMCC or CDT?

Does the media refer more to IMCC or CDT?

Which has better earnings and valuation, IMCC or CDT?

Is IMCC or CDT more profitable?

Do insiders and institutionals believe in IMCC or CDT?

Summary

How does IM Cannabis compare to Clearmind Medicine?

Which has more volatility & risk, IMCC or CMND?

Which has preferable valuation & earnings, IMCC or CMND?

Does the media refer more to IMCC or CMND?

Do analysts prefer IMCC or CMND?

Do institutionals and insiders believe in IMCC or CMND?

Is IMCC or CMND more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools